Cargando…

Ruthenium Complex with Benznidazole and Nitric Oxide as a New Candidate for the Treatment of Chagas Disease

BACKGROUND: Chagas disease remains a serious medical and social problem in Latin America and is an emerging concern in nonendemic countries as a result of population movement, transfusion of infected blood or organs and congenital transmission. The current treatment of infected patients is unsatisfa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sesti-Costa, Renata, Carneiro, Zumira A., Silva, Maria C., Santos, Maíta, Silva, Grace K., Milanezi, Cristiane, da Silva, Roberto S., Silva, João S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183476/ https://www.ncbi.nlm.nih.gov/pubmed/25275456 http://dx.doi.org/10.1371/journal.pntd.0003207

Ejemplares similares

From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease
por: Gomes, Daniele Cavalcante, et al.
Publicado: (2023)

Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease
por: Fragata-Filho, Abilio Augusto, et al.
Publicado: (2016)

Benznidazole, itraconazole and their combination in the treatment of acute experimental Chagas disease in dogs
por: Cunha, Eleonora Lima Alves, et al.
Publicado: (2019)

Hepatic changes by benznidazole in a specific treatment for Chagas disease
por: Pavan, Tycha Bianca Sabaini, et al.
Publicado: (2018)

In Vitro and In Vivo Trypanocidal Activity of H(2)bdtc-Loaded Solid Lipid Nanoparticles
por: Carneiro, Zumira A., et al.
Publicado: (2014)

Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil
por: Gontijo, Maria Katarine Costa Lucas, et al.
Publicado: (2020)

Clinical Follow-Up of Responses to Treatment with Benznidazol in Amazon: A Cohort Study of Acute Chagas Disease
por: Pinto, Ana Yecê das Neves, et al.
Publicado: (2013)

Traditional use of benznidazole with weekly clinical follow-up indicate to be an important approach for the etiologic treatment of Chagas disease
por: Sperandio da Silva, Gilberto Marcelo
Publicado: (2022)

Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study
por: Cardoso, Clareci Silva, et al.
Publicado: (2018)

Benznidazole Use among Patients with Chronic Chagas' Cardiomyopathy in an Endemic Region of Brazil
por: Ferreira, Ariela Mota, et al.
Publicado: (2016)

Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy
por: Silva Grijó Farani, Priscila, et al.
Publicado: (2023)

The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance
por: Almeida-Silva, Juliana, et al.
Publicado: (2022)

Benznidazole decreases the risk of chronic Chagas disease progression and cardiovascular events: A long-term follow up study
por: Hasslocher-Moreno, Alejandro M., et al.
Publicado: (2020)

Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2016)

Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease
por: Assíria Fontes Martins, Tassiane, et al.
Publicado: (2015)

Benznidazole Treatment: Time- and Dose-Dependence Varies with the Trypanosoma cruzi Strain
por: Fonseca, Kátia da Silva, et al.
Publicado: (2021)

Doxycycline and Benznidazole Reduce the Profile of Th1, Th2, and Th17 Chemokines and Chemokine Receptors in Cardiac Tissue from Chronic Trypanosoma cruzi-Infected Dogs
por: de Paula Costa, Guilherme, et al.
Publicado: (2016)

Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease
por: de Oliveira-Silva, Jaquelline Carla Valamiel, et al.
Publicado: (2015)

Access to benznidazole for Chagas disease in the United States—Cautious optimism?
por: Alpern, Jonathan D., et al.
Publicado: (2017)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
por: Vázquez, Cristina, et al.
Publicado: (2023)

Treatment With Suboptimal Dose of Benznidazole Mitigates Immune Response Molecular Pathways in Mice With Chronic Chagas Cardiomyopathy
por: Farani, Priscila Silva Grijó, et al.
Publicado: (2021)

Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole
por: Calvet, Claudia Magalhães, et al.
Publicado: (2020)

Benznidazole as Prophylaxis for Chagas Disease Infection Reactivation in Heart Transplant Patients: A Case Series in Brazil
por: Rossi Neto, Joao Manoel, et al.
Publicado: (2020)

Memory impairment in chronic experimental Chagas disease: Benznidazole therapy reversed cognitive deficit in association with reduction of parasite load and oxidative stress in the nervous tissue
por: Vilar-Pereira, Glaucia, et al.
Publicado: (2021)

The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Population pharmacokinetic modeling of benznidazole in Brazilian patients with chronic Chagas disease
por: Frade, Virgínia Paula, et al.
Publicado: (2022)

Ruthenium Complexes as NO Donors for Vascular Relaxation Induction
por: Galvão de Lima, Renata, et al.
Publicado: (2014)

Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2013)

Correction: The fecal, oral, and skin microbiota of children with Chagas disease treated with benznidazole
por: Robello, Carlos, et al.
Publicado: (2019)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole
por: Yoshioka, Kota, et al.
Publicado: (2020)

Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease
por: Rial, Marcela S., et al.
Publicado: (2017)

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
por: Aguilera, Elena, et al.
Publicado: (2018)

Benznidazole
por: Soares-Sobrinho, José Lamartine, et al.
Publicado: (2008)

Non-peptidic Cruzain Inhibitors with Trypanocidal Activity Discovered by Virtual Screening and In Vitro Assay
por: Wiggers, Helton J., et al.
Publicado: (2013)

Anti-Trypanosoma cruzi antibody profiling in patients with Chagas disease treated with benznidazole assessed by genome phage display
por: Rodriguez Carnero, Luis Antonio, et al.
Publicado: (2023)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
por: Fernández, Marisa Liliana, et al.
Publicado: (2016)

Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease
por: Olivera, Mario J., et al.
Publicado: (2017)

Efficacy of the Benznidazole+Posaconazole combination therapy in parasitemia reduction: An experimental murine model of acute Chagas
por: Echeverría, Luis Eduardo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1qkogr5c7k3e0mv4e3kcoepqhk